Introduction
============

DNA methylation is a major epigenetic alteration that plays a key role in the occurrence of cancer [@B1]. It is a genetically modified style with reversibility and heredity and has important biological significance, manifested in the control of tissue-specific gene expression, maintenance of chromosomal integrity [@B2]. The methylation of tumor-associated genes has been shown to be one of the important mechanisms involved in the process of gene transcriptional silencing and regulating gene expression then results in tumor suppressor gene inactivation, oncogene activation, eventually leading to tumorigenesis [@B3], [@B4]. The feasible technology to detect methylated DNA allows us to use DNA methylation as a molecular biomarker for cancer prediction and prognosis [@B5]-[@B7].

DNA mismatch repair (MMR) system is one of key link in suppressing tumor formation, which can repair mismatched DNA in DNA replication to maintain genome stability. The MMR system contains a few key genes like *MLH1, MSH2, MSH6* and *PMS2 etc.*, from which encoding protein can form heterodimer to identified mismatched bases, together with other repair proteins, to complete DNA repair [@B8]. It is well accepted that the inactivation of MMR function is derived from germline mutation, somatic mutations or epigenetic silencing. The abnormalities of MMR can lead to microsatellite instability (MSI), which is short (1-6 base pairs) tandem repeats, spreading throughout the genome, being the identified heteromorphosis related to the occurrence and development of cancer. And colorectal cancers with MSI-H have an improved prognosis [@B9].MMR preferentially protects genes from mutation and has important consequences for understanding the evolution of genomes during both natural selection and human tumor growth. MMR deficiency disproportionately increases the numbers of single-nucleotide variants in genes [@B10].

*MLH1* gene is localized at chromosome 3p22.2. It is responsible for the replacement of the mispaired nucleotides in the genome during the replication [@B11]. As a key member of MMR system,*MLH1* is epigenetically inactivated via methylation of the gene promoter that lead to the deficiency of MMR. For example, in colorectal cancer (CRC) MSI resulted from methylation of *MLH1* gene promoter, can cause its transcriptional silencing and affect other growth regulation and apoptosis-related genes, leading to the carcinogenesis of CRC. The majority of sporadic MSI tumors are caused by an epigenetic inactivation of MLH1 or MSH2. MMR deficient tumors have 10-100 times more somatic mutations than MMR proficient (pMMR) tumors leading to increased neoantigen burden and immunogenicity [@B12]. Similarly, *MLH1* hypermethylation is also preceded by malignant proliferation of other cancers such as endometrial cancer, lung cancer, breast cancer, esophageal cancer and gastric cancer [@B13]-[@B20]. So the detection of *MLH1* methylation can be used for prediction of tumorigenesis.

Gastric cancer (GC) is the third major cause of cancer-related deaths in the world [@B21]. Environmental, genetic, diet and other predisposing factors contribute to the development of gastric cancer. In recent years, more and more evidence shows that methylation of tumor suppressor gene is not be ignored risk factor in gastric carcinogenesis. In 2014, Cancer Genome Atlas Research classified GC into four pathological subtypes, in which MSI type including MMR methylation was proposed for the first time [@B22]. Along with the popularization of the classification, MMR methylation in gastric cancer had been widely studied. But the relevance between *MLH1* methylation and GC, especially the role of *MLH1* methylation on the risk prediction and prognosis of GC, remains controversial.

Here, we conducted a systematic review and meta and bioinformatic analysis to evaluate the correlation between *MLH1* promoter methylation and GC through comparing cancer with healthy controls. Moreover, we also assessed the correlation between *MLH1* promoter methylation and biological behavior as well as prognosis of GC by comparing cancer with different clinical pathological parameters and survival status. This study expects to get more credible information to assess the role of *MLH1* methylation in gastric cancer prediction and prognosis.

Methods
=======

Search strategy
---------------

Electronic databases, including PubMed, Web of Science, Embase, BIOSIS, Chinese National Knowledge Infrastructure (CNKI), Wanfang Data were used to systematically look for related studies published in English and Chinese until May 1, 2017. The following terms were searched: methylation or DNA methylation or hypermethylation, gastric cancer or gastric carcinoma, and MLH1 or hMLH1. Furthermore, references that were cited in each included study were also searched manually to identify potential relevant studies.

Inclusion and exclusion criteria
--------------------------------

Eligible studies had to meet the following inclusion criteria: 1) Research topic focused on the *MLH1* methylation and gastric cancer; 2) Case-control or cohort studies; 3) The studies with sufficient data for calculating odds ratios (ORs) and 95% confidence intervals (CIs); 4) Subjects investigated had a defined diagnosis by pathology. 1) Researches not related to methylation; 2) Researches not related to MLH1 methylation or methylation sites were not in the promoter region; 3) Researches not focus on GC, such as gastric ulcer and gastric functional dyspepsia and precancerous lesions; 4) Researches that selected subgroups (such as selected based on age, sex, and tumor stage); 5) Case reports and reviews; 6) Animal and cell studies. 7) Paper with insufficient or duplicated data. For duplicated data, only the most comprehensive studies were included.

Data extraction
---------------

Data from the included studies were extracted independently by two authors, Shixuan Shen and Xiaohui Chen. The information was collected from extracted data including: the first author\'s name, publication year, country where study conducted, detection method, sample type, the frequency of *MLH1* methylation in case and control groups, clinicopathological parameters (i.e., Lauren classification, tumor invasion, lymph node status, distant metastasis and tumor stage) and survival status. The two authors reached a consensus on each item. If the data could not be obtained from the original studies, we would contact the corresponding author on reasonable request. If the authors are not convenient or willing to cooperate, we would exclude this study.

Quantity assessment
-------------------

The Newcastle-Ottawa scale (NOS) with eight items was used to evaluate the quality of the included studies using three parameters: selection (four items, each awarded one star), comparability (one item, which can be awarded up to two stars) and exposure/outcome (three items, each awarded one star) [@B23]. NOS scores of 1-3, 4-6 and 7-9 were considered low, medium and high quality, respectively. Only studies with scores ≥ 7 were included in the analysis.

Bioinformatical analysis
------------------------

We screened the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo>) which is a public repository that archives and freely distributes microarray [@B24] and use GEO2R (NCBI) to compare the methylation level in GC and normal tissues and then analyzed the association between *MLH1* promoter methylation and the GC risk.

The information of 338 GC patients was downloaded from the Cancer Genome Atlas (TCGA) database by TCGA-assembler in R software. We put the raw data into analyzing the role of *MLH1* promoter methylation in the GC risk prediction, behavior determination and prognosis evaluation.

Statistical analyses
--------------------

Stata 11.0 (Stata Corporation, TX, USA) were used in this meta-analysis. The link strength between *MLH1* methylation and GC risk or clinicopathologic features was estimated by odds ratio (OR) with its 95% CI. The heterogeneity among the studies was assessed by Q-test and further quantified by the I^2^ metric [@B25]. If there was substantial heterogeneity (P\<0.05 or I^2^ \> 50%), a random effect model was used to pool the ORs; otherwise, a fixed effect model was employed [@B26]. P value \< 0.05 was considered statistically significant. Egger\'s linear regression test were applied to examine whether the results existed publication bias [@B27]. All tests were two-sided, and P\<0.05 indicated statistical significance. When heterogeneity was shown, sensitivity analysis was performed to identify heterogeneity sources. Subgroup analysis was carried out to explore the effect of country, ethnicity, and methylation testing methods.

SPSS 22.0 software (SPSS, Chicago, IBM, USA) were used in the current bioinformatics analysis. Person χ^2^ test was applied to evaluate the association of *MLH1* methylation with clinicopathologic features. Kaplan-Meier curves were drew to outline the survival status and the differences between the groups were analyzed using the log-rank test. P values\<0.05 were considered statistically significant.

Results
=======

Meta-analysis
-------------

### Study characteristics

According to the literature selection criteria and search strategy, 26 studies [@B11], [@B17], [@B18], [@B28]-[@B50] were included in the present meta-analysis, including 2365 gastric cancer cases and 1563 nonmalignant controls. The study screening process is shown in Figure [1](#F1){ref-type="fig"}. Among these studies, 16 studies reporting 1794 cases and 1563 nonmalignant controls were selected to evaluate the relevance between *MLH1* methylation and GC risk. Furthermore, 10 studies, including 476 intestinal GC and 290 diffuse GC, estimated the Lauren classification-based association; 9 studies assessed the tumor invasion-based association; 16 studies explored the lymph node metastasis-based association; 8 studies appraised the distant metastasis-based association and 9 studies including 219 stage Ⅰ-Ⅱ patients and 422 stage Ⅲ-Ⅳ patients evaluated the tumor stage-based association. These 26 studies were published between 2008 and 2016. All of them were written in English or Chinese. Of the studies, 10 came from China, 4 came from Brazil ,3 came from Japan, 2 came from Korea, 2 came from India, 1 came from Egypt, 1 came from Iran, 1 came from Lithuania, 1 came from Russia and 1 came from Spain, severally. The basic characteristics of all the included studies were summarized in Table [1](#T1){ref-type="table"}. The NOS results showed that all the involved studies were at a higher quality level with scores ≥ 7. Full results of NOS quality assessment were summarized (Table [S1](#SM0){ref-type="supplementary-material"}).

### *MLH1* promoter methylation and GC risk

In the identification of GC and controls, slight heterogeneity was existed (I^2^ = 36.46% and P =0.006), therefore a random effect model was performed. Our results exhibited that the frequency of *MLH1* promoter methylation was enhanced in patients with GC compared with control groups (OR= 4.895, 95% CI: 3.149-7.611, P\<0.001, Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}), showing that the *MLH1* methylation status was significantly associated with the GC risk. We furthermore performed subgroup analyses stratified by country, ethnicity, testing methods, and materials respectively. Country-specific OR showed an increased risk for individuals with the *MLH1* methylation compared with those without *MLH1* methylation in China (OR=15.222, 95% CI: 5.395-42.952, P\<0.001) and Japan (OR=2.452, 95% CI: 1.158-5.193, P\<0.001). Then we calculated the pool OR for *MLH1* promoter in the Asian subgroup, that was 5.949 (95% CI: 3.393-10.431, P\<0.001) within a random effect model, and that for the Negroid subgroup was 5.017 (95% CI: 2.510-10.027, P\<0.001) under a random effect model. But for the Caucasian subgroup, the pool OR was 1.744 (95% CI: 0.871-3.491, P= 0.116), showing no significance with *MLH1* promoter methylation. Subgroup analysis based on the testing methods indicated that considerably increased risks were found in both MSP (OR=5.426, 95% CI: 3.215-9.156) and Methylight (OR=3.168, 95% CI:1.521-6.599) groups (Table [2](#T2){ref-type="table"}). Testing materials analysis revealed that the pool OR was 4.472 (95% CI: 2.874-6.959, P\<0.001) for the tissue and 12.538 (95% CI:1.861-84.463, P=0.009) for the blood. That is, the GC risk was significantly raised in both tissue and blood subgroup.

### *MLH1* promoter methylation and GC clinicopathologic features

Fixed-effects model was applied for Lauren classification, tumor invasion, distant metastasis status and tumor stage (all P~h~ \> 0.1) and random-effects model was used for lymph node status (P~h~ \< 0.1). There was no significant difference in *MLH1* methylation detected in Lauren classification (OR=0.878, 95% CI: 0.619-1.244, P=0.463, Figure [3](#F3){ref-type="fig"}a), tumor invasion (OR=0.844, 95% CI: 0.568-1.253, P=0.400, Figure [3](#F3){ref-type="fig"}b), lymph node status (OR=0.929, 95% CI: 0.620-1.390, P=0.720, Figure [3](#F3){ref-type="fig"}c), distant metastasis status (OR=0.819, 95% CI: 0.481-1.396, P=0.464, Figure [3](#F3){ref-type="fig"}d) and tumor stage (OR=0.687, 95% CI: 0.455-1.039, P=0.075, Figure [3](#F3){ref-type="fig"}e) in gastric cancer(Table [3](#T3){ref-type="table"}).

### Sensitivity analysis

For those groups which existed slight heterogeneity (GC risk I^2^=36.46%, P~h~=0.006, Lymph node status I^2^=37.30%, P~h~=0.072, Figure [4](#F4){ref-type="fig"}), Sensitivity analysis was subsequently performed to detect the influence of individual study on the pooled estimate by omitting one study from the pooled analysis each time. The exclusion of each single study did not significantly change the pooled OR, suggesting that the results of the meta-analysis were robust.

### Publication bias

As indicated in Table [3](#T3){ref-type="table"}, slight publication bias was perceived by Egger\'s test and Begg\'s test in the contrast of cancer and control groups, and also in distant metastasis as well as tumor stage subgroups. There was no obvious publication bias stated in other analytic subgroups. (all P \> 0.05).

Bioinformatical analysis
------------------------

### *MLH1* promoter methylation and GC risk

We extracted 2 GEO series (GSEs) within 180 GEO series both related to gastric cancer and methylation. All two GSEs were solely derived from human tissues and used methylation probe to detect the methylation rate. We screened two methylation location, cg18320188 and cg02279071 on the CpG island of *MLH1* DNA sense strand. They located on chromosome 3 (37008972 - 37010459). Their sequences were showed in Table [S2](#SM0){ref-type="supplementary-material"}. After analyze the data using GEO2R, we found that *MLH1* promoter methylation showed a high level in GC compared to normal tissues (P=0.0149 from GSE30601 probe cg18320188, P=0.0442 from GSE25869 probe cg02279071).

Then we search data covering DNA methylation and gene expression on the website of MethHC (A database of DNA Methylation and gene expression in Human Cancer <http://methhc.mbc.nctu.edu.tw/php/index.php>) and the TCGA (The Cancer Genome Atlas) [@B51]. The data showed that there were significant differences in methylation levels between cancer and normal tissues (P\<0.005). All the results expounded that *MLH1* methylation status was considerably related with the GC risk.

### *MLH1* promoter methylation and GC clinicopathologic features

We analyzed the association between*MLH1* methylation and clinicopathologic features such as Lauren classification, tumor invasion, distant metastasis status and tumor stage using the same methylation probe as GSE30601 cg18320188 and GSE25869 cg02279071. No correlation was found between the two. (Table [4](#T4){ref-type="table"}).

### *MLH1* promoter methylation and GC prognosis

Firstly, the influence of *MLH1* methylation on recurrence free survival (RFS) time was assessed. A total of 338 patients with recurrence free survival time related data were enrolled in this section. Analytic results of Kaplan-Meier curve and Log-Rank test suggested that *MLH1* methylation was not significantly associated with RFS (Table [5](#T5){ref-type="table"}, Figure [5](#F5){ref-type="fig"}). And then, the association between *MLH1* methylation and overall survival time (OS) was also evaluated. Similar to RFS, the results did not show any correlation between *MLH1* methylation and OS of GC (Table [5](#T5){ref-type="table"}, Figure [5](#F5){ref-type="fig"}).

Discussion
==========

The methylation frequency of the *MLH1* promoter was inconsistent in GC with a range from 4% to 100% [@B37]. Thus, the association between *MLH1* promoter methylation and GC exists controversy. To get a more credible conclusion, we performed a systematic review and meta and bioinformatic analysis using the previously published studies and database to assess the relevance between *MLH1* methylation and GC. Our study showed a strong correlation between *MLH1* methylation and GC risk, indicating that *MLH1* methylation could predict the occurrence of gastric cancer as a convincing biomarker. No significant correlation was found between *MLH1* methylation and GC clinicopathological behavior as well as prognosis.

In the present meta-analysis, 2365 GC cases and 1563 control samples, from 26 studies were selected totally. Compared with the controls, the accumulated OR of *MLH1* methylation in GC patients was 4.895 (95% CI: 3.149-7.611, P\<0.001). It was in accordance with earlier studies in which the frequency of *MLH1* promoter methylation in GC was enhanced compared with control groups [@B30], [@B34], [@B37]. Our bioinformatics analysis based on GEO and TCGA also showed that *MLH1* promoter methylation sustained a high level in GC compared to normal tissues (P=0.0149, P=0.0442 respectively). The results drew from both meta and bioinformatics analysis suggested that the methylation of *MLH1* was significantly associated with increased GC risk. The consequence may be caused by two main reasons. Firstly, Mismatch repair (MMR) deficiency leads to a tumour phenotype known as microsatellite instability (MSI), in which cells accumulate genetic errors [@B19]. *MLH1* is a functional member of DNA MMR system*,* which is responsible for the replacement of the mispaired nucleotides in the genome during the DNA replication [@B11]. When performing mismatch repair function, the heteroduplex composed of *MLH1* and *PMS2* could combine with DNA fragment thereby trigger the repair process. In addition to that it reactivates cell cycle arrest and caspase-mediated apoptosis in response to DNA damage, promotes cell mobility and interacts with other significant cell signaling proteins [@B52]-[@B55]. The aberration of the *MLH1* function could lead to the dysfunction of DNA MMR system therefore result in the GC carcinogenesis [@B56]. Secondly, *MLH1* is also a tumor suppressor gene, which expression is repressed by promoter methylation. And that\'s exactly one of the key features of cancer [@B57]. As a tumor suppressor gene *MLH1* silencing mediated by aberrant promoter DNA hypermethylation could lead to the tumor information [@B58]. Based on the present results and analysis, we could conclude that *MLH1* methylation significantly elevated the risk of GC and might be a probable biomarker for the prediction of GC.

The current meta and bioinformatic analysis revealed that no significant difference of *MLH1* methylation in relation to clinicopathological features, such as Lauren classification, tumor invasion, lymph node status, distant metastasis and tumor stage in GC (all P \> 0.1), suggesting that the methylation status of *MLH1* promoter may not affect the biological behavior of GC. The phenomenon that *MLH1* methylation increased the risk of GC but not related with clinicopathological features hinted that DNA methylation occurs early in the multistep process of gastric carcinogenesis. Bischoff *et al.* reported that *MLH1* methylation with a consequent protein decrease occurred early during endometrial carcinogenesis [@B13]. And the coherent conclusions were also elucidated in lung cancer and breast cancer. [@B14]-[@B16]. Thus, we can infer that *MLH1* methylation may contribute to initial carcinogenesis but not progression of GC.

It has been reported that *MLH1* methylation are associated with poor prognosis in cancers, such as in non-small cell lung cancer and ovarian cancer after chemotherapy [@B59], [@B60]. But the current bioinformatics analysis revealed that no relationship between *MLH1* methylation with the prognosis of GC including RFS and OS based on the data from TCGA database. Only one study in the meta-analysis revealed that among oxaliplatin-treated patients, OS was longer in the *MLH1* unmethylated group than in the *MLH1* methylated group [@B32]. The phenomenon suggested that *MLH1* methylation may not affect the prognosis of GC. The different effects of *MLH1* methylation on prognosis in different tumors may be due to the organ specificity. There may exist some gastric specific indicators commonly affected the consequence of *MLH1* methylation and prognosis [@B61]. Further expanding of the sample size could be conduct to verify the impact of *MLH1* methylation on GC prognosis.

Our study had some limitations. First, our meta-analysis could not adjust for confounding factors such as age, sex, smoking behavior, or *H.pylori* infection due to some relevant data could not be extracted. Second, the studies included was only searched by English and Chinese, the other language of studies were not included therefore some important researches may be omitted. Third, up to now, few studies reported the association of *MLH1* methylation with prognosis of GC. On this point, we did only the bioinformatics analysis and failed to meta-analysis. There is a need to strengthen the prognosis-based association study in the future. Fourth, Heterogeneity existed in our meta-analysis. Although we try to eliminate the heterogeneity by subgroup analysis according to the potential heterogeneous factors, such as geographic region, ethnicity, testing methods and materials, there is still some heterogeneity in this meta-analysis because some original studies did not provide the necessary information.

In summary, this systematic review and meta and bioinformatic analysis showed a strong correlation between *MLH1* methylation and GC risk and no significant correlation was found between *MLH1* methylation and GC clinicopathological behavior as well as prognosis. The present results suggest that *MLH1* methylation can be used as a favorable molecular marker for the prediction of GC and it might not affect GC behavior. Further study could be conducted to verify the impact of MLH1 methylation on GC prognosis.
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###### 

Characteristics of the studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author              Year   Country       Ethnicity    Method       Sample type   Case(M/U)   Control(M/U)   Lauren classification (M/U)   Tumor invastion (M/U)   Lymph node status(M/U)   Distant metastasis(M/U)   TNM stage\                                    
                                                                                                                                                                                                                       (M/U)                                         
  ------------------- ------ ------------- ------------ ------------ ------------- ----------- -------------- ----------------------------- ----------------------- ------------------------ ------------------------- ------------ -------- -------- ------ ------- -------
  Sabry, D            2016   Egypt         Negroids     MethyLight   Tissue        10/0        20/9           NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Kupcinskaite, R     2016   Spain         Caucasians   MSP          Tissue        25/56       NA             13/29                         12/27                   7/14                     18/42                     11/17        14/39    NA       NA     NA      NA

  Yoda, Y             2015   Japan         Asians       Bead array   Tissue        7/43        0/6            NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Teng, Y             2015   China         Asians       MSP          Tissue        13/27       0/24           NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Liu, L              2015   China         Asians       MSP          Tissue        24/26       1/29           NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Li, Y               2015   China         Asians       MSP          Tissue        22/80       NA             13/51                         9/24                    3/10                     19/70                     10/26        12/54    21/73    1/7    6/13    16/67

  Zhou, W             2015   China         Asians       MSP          Blood         36/47       0/20           NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Wang, M             2014   China         Asians       MethyLight   Tissue        20/114      1/45           5/47                          12/55                   NA                       NA                        NA           NA       18/94    2/20   NA      NA

  Jin, J              2014   China         Asians       MSP          Tissue        16/267      0/283          NA                            NA                      6/116                    10/151                    6/152        10/115   13/245   3/22   NA      NA

  Moghbeli, M         2014   Iran          Asians       MSP          Tissue        13/38       NA             7/29                          5/8                     4/15                     9/23                      2/6          11/32    NA       NA     3/17    10/21

  Guo, H              2014   China         Asians       MSP          Tissue        16/54       NA             NA                            NA                      6/20                     10/34                     6/15         10/39    15/51    1/3    8/25    8/29

  Ying, J             2014   China         Asians       MSP          Tissue        29/91       10/110         NA                            NA                      NA                       NA                        3/13         26/78    22/75    7/16   3/15    26/76

  Xiong, H. L         2013   China         Asians       MSP          Blood         19/394      0/413          NA                            NA                      8/170                    11/224                    9/222        10/172   15/362   4/32   NA      NA

  Kupcinskaite, R     2013   Lithuania     Caucasians   MSP          Tissue        22/47       16/53          10/25                         11/21                   NA                       NA                        10/15        11/31    NA       NA     4/9     17/36

  Alvarez, M. C       2013   Brazil        Negroids     MSP          Tissue        36/56       12/85          NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Kim, K. J           2013   South Korea   Asians       MethyLight   Tissue        80/22       NA             72/17                         1/3                     19/9                     61/13                     33/9         47/13    NA       NA     47/15   33/7

  Wani, M             2012   India         Asians       MSP          Tissue        51/19       14/56          NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Mir, M. R           2012   India         Asians       MSP          Tissue        104/26      82/48          NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Alves, M. K         2011   Brazil        Negroids     MSP          Tissue        25/51       NA             15/33                         10/18                   NA                       NA                        NA           NA       NA       NA     NA      NA

  Mikata, R           2010   Japan         Asians       MSP          Tissue        2/19        1/20           NA                            NA                      NA                       NA                        0/6          2/13     NA       NA     0/8     2/11

  Hiraki, M           2010   Japan         Asians       MethyLight   Tissue        32/17       21/28          17/10                         7/15                    NA                       NA                        7/13         25/4     NA       NA     12/12   20/5

  Ferrasi, A. C       2010   Brazil        Negroids     MSP          Tissue        27/62       NA             19/38                         8/23                    NA                       NA                        6/11         21/50    NA       NA     NA      NA

  Gu, M               2009   Korea         Asians       MSP          Tissue        39/15       23/31          NA                            NA                      NA                       NA                        NA           NA       NA       NA     NA      NA

  Moura Lima, E       2008   Brazil        Negroids     MSP          Tissue        10/36       0/20           6/20                          4/16                    3/9                      7/27                      5/11         5/25     10/31    0/5    NA      NA

  Kolesnikova, E. V   2008   Russia        Caucasians   MSP          Blood         5/15        2/20           NA                            NA                      2/8                      3/7                       2/7          3/8      4/12     1/3    NA      NA

  Wu, A               2008   China         Asians       MSP          Tissue        18/42       0/60           NA                            NA                      NA                       NA                        14/37        4/5      NA       NA     5/17    13/25
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, methylations; U, unmethylations; MSP, methylation-specifc PCR; NA, not available

###### 

Subgroup analysis of *MLH1* promoter methylation in gastric cancers compared with controls.

                        Studies   Heterogeneity test           Test for overall effect                           
  --------------------- --------- -------------------- ------- ------------------------- ----------------------- ---------
  Gastric cancer risk   19        36.46%               0.006                             4.895 (3.149-7.611)     \<0.001
  Subgroup                                                                                                       
  Country                                                                                                        
  China                 8         46.20%               0.072                             15.222 (5.395-42.952)   \<0.001
  Japan                 3         0.00%                0.989                             2.452(1.158-5.193 )     \<0.001
  Ethnicity                                                                                                      
  Asians                14        55.70%               0.006                             5.949 (3.393-10.431)    \<0.001
  Caucasians            2         0.00%                0.436                             1.744 (0.871-3.491)     0.116
  Negroids              3         0.00%                0.729                             5.017 (2.510-10.027)    \<0.001
  Methods                                                                                                        
  MSP                   15        59.20%               0.002                             5.426 (3.215-9.156)     \<0.001
  Methylight            3         0.00%                0.408                             3.168 (1.521-6.599)     0.002
  Bead array            1         NA                   NA                                2.241 (0.114-44.084)    0.595
  Materials                                                                                                      
  Tissue                16        50.30%               0.011                             4.472 (2.874-6.959)     \<0.001
  Blood                 3         46.00%               0.157                             12.538 (1.861-84.463)   0.009

**Note:** Values in bold indicate statistical significance.

**Abbreviations:** CI, confidence interval; P~h~, P-value of Q test for heterogeneity among studies; OR, odds ratio; NA, not available

###### 

Association of *MLH1* promoter methylation with clinicopathologic features in gastric cancer.

  Clinicopathological features   Studies   Heterogeneity test   Statistical model   Test for overall effect   Begg\'s test          Egger\'s test                            
  ------------------------------ --------- -------------------- ------------------- ------------------------- --------------------- --------------- ------- ------- -------- -------
  Gastric cancer risk            19        36.46%               0.006               R                         4.895 (3.149-7.611)   **\<0.001**     0.190   0.234   3.110    0.006
  Lauren classification          10        1.30%                0.426               F                         0.878 (0.619-1.244)   0.463           0.000   1.000   1.470    0.180
  Tumor invasion                 9         0.00%                0.949               F                         0.844 (0.568-1.253)   0.400           0.310   0.754   0.250    0.806
  Lymph node status              15        37.30%               0.072               R                         0.929 (0.620-1.390)   0.720           0.990   0.322   -1.050   0.314
  Distant metastasis             8         0.00%                0.479               F                         0.819 (0.481-1.396)   0.464           1.360   0.174   2.050    0.087
  Tumor stage                    9         0.70%                0.428               F                         0.687 (0.455-1.039)   0.075           0.620   0.536   -0.160   0.877

**Abbreviations:** R, random effect model; F, fixed effect model

###### 

Association of *MLH1* promoter methylation with clinicopathologic features in gastric cancer based on bioinfromatic analysis

  Clinical features           Methylation status                                  
  --------------------------- -------------------- ----- ----- ------ ----- ----- ------
  **Lauren classification**   Intestinal           85    68    0.57   82    71    0.27
  Diffuse                     36                   34          32     38          
  **Tumor invastion**         T1-T2                42    43    0.90   50    35    0.05
  T3-T4                       127                  126         118    135         
  **Lymph node status**       Negative             55    50    0.56   58    47    0.19
  Positive                    111                  116         108    119         
  **Distant metastasis**      Negative             152   149   0.79   155   146   0.43
  Positive                    9                    10          8      11          
  **TNM stage**               stage Ⅰ-Ⅱ            79    75    0.90   83    71    0.18
  stage Ⅲ-Ⅳ                   88                   86          81     93          

###### 

Association of *MLH1* promoter methylation with prognosis in gastric cancer based on bioinfromatic analysis.

  Methylation probe   RFS             OS                                 
  ------------------- --------------- ------ ------ ------ ------ ------ ------
  **cg18320188**      Unmethylation   1676   3.09   0.08   1153   0.06   0.81
  Methylation         1376                          869                  
  **cg02279071**      Unmethylation   1184   2.21   0.14   869    0.63   0.43
  Methylation         NA                            1043                 
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